THRYV-1257 / Thryv Therap - LARVOL DELTA

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting (Canada Newswire) - "Thryv Therapeutics Inc...announced today FDA clearance of its Investigational New Drug application (IND) for THRV-1257. THRV-1257 is being investigated for the treatment of advanced Anaplastic Thyroid Cancer (ATC), including those patients with the common BRAF mutation V600E. The first in human study will determine the optimal dosing of THRV-1257 in patients with solid tumors, followed by treatment in combination with approved cancer therapies...At the same time, the company announces acceptance of a late breaking poster that will be presented at the upcoming American Thyroid Association (ATA) annual meeting in Washington DC, on September 30th, 2023, from 10:00 a.m. to 1:00 p.m. The presentation will highlight in vitro and in vivo preclinical results of SGK1 inhibition in models of ATC....Phase 1 TRIFEKTA clinical study expected to start in Q4 2023."

IND • New P1 trial • Preclinical • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma

Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec (PRNewswire) - "Thryv Therapeutics Inc. announced today the closing of a USD $5,000,0000 convertible note investment by Investissement Québec (IQ)...The proceeds of the convertible note will be used to immediately accelerate Thryv's portfolio programs....Thryv has generated highly encouraging new in vivo animal data with its lead oncology compound demonstrating tumor regression in treatment resistant anaplastic thyroid carcinomas. This new data, coupled with helpful feedback from the US Food and Drug Administration regarding Thryv's initial clinical plan, will allow the company to submit its Investigational New Drug Application (IND) this summer."

Financing • IND • Preclinical • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma